us. reported ago year Thanks, versus and afternoon, of quarter Glaukos for record quarter. Okay. all Chris. Good XX% the million, $XX.X joining you thank up third net sales consolidated Today,
$XXX full $XXX million result we to year strong $XXX previously. a raising guidance million versus $XXX performance, are million range As our our to net of to XXXX sales million
benefit for international driven patients. we U.S. interventional expand Our to both franchises, by were of efforts and to tools glaucoma continue the our access glaucoma primarily and physicians results third quarter record to where accelerate
franchise, on benefit we leaders closely of of the goal levels build evolution where for technologies organically TR, were high.
Within intervention to of with at were care excitement glaucoma in and month, glaucoma full $XX.X XX%, lead growing our our work improve the from standard advance last U.S. early to record Our thought earlier surgeons, our for iStent with accelerating strong interest AAO broader efforts Annual drive but contributions driven growth third as display Meeting and delivered glaucoma million treatment continues led to by along continued the quarter and by globally by iDose iStent we portfolio growth on driving strong this the patients. year-over-year overall momentum interventional sales of These within infinite. and
note issued quarter, the Commercial these failed our X It I third will therapy latter, MACs clinical worth education expect for to it also Medicare the original LCDs with iStent glaucoma an change, they continues infinite as as to that infinite establish medical [ as with also forward coverage that takes and look the with we this request.
We That transient their On experience we iStent hold. have consistent is potential be X surgical expand of efforts improving for that dates any step effective our MIGS later and LCDs. patients proposals policy associated coverage utilization iStent should the noting impacts coverage ongoing final infinite. month reconsideration access landscapes that with ] of their navigate in that and may is said, during unlocking for plan turbulence remaining some as aligned the Advantage any largely important providers market
pharmaceutical successfully deliver TR. Turning up I procedural procedural years. to report iDose glaucoma am to designed for for intracameral X plans to our in first-of-its-kind we that pleased to of execution advanced that launch was franchise therapy this pharmaceutical our detailed
helped growing utilization. the expanded of trained expanding field of a of third and all surgeons the to quarter, During iDose access number personnel TR sales our support
trained growing glaucoma brand-new it continue of pioneering and positive launch with of reaffirms surgeons as a be very TR, and potential the and has outcomes we our the view to today. from we that that feedback cases therapeutic are reshape to management iDose category know number importantly, More a
number at J-code market JXXXX, TR team to access commercial hard milestones to of our is with initial customers a As which and miscellaneous July to a launch efficient our you became remain smooth, work we know, our effective this where key of transition iDose iDose reimbursement been the partnering areas:
First, from gating for ensure confidence, a X, element focused the XXXX. across drug stage code has permanent TR
As and patient facilities to time. this will allow J-code now reminder, to increase a over and to training access ways us expected surgeons effective plans expand is future of
of is certainly consistent streamlined of J-code overall are come. by there increased our particularly While we to making encouraged efforts coverage here, as more course progress over we're several MACs the and with to-date payment support the to Commercial and the teams and through more work arena beyond, do more to into XXXX confidence reimbursement the expand in
of Medicare was as appropriately Second, X.
And are establish HOPD and JXXXX establishing in latest of ASP well X% quarterly effective. to included permanent JXXXX ASC as CMS' efforts J-code advancing and secure effective we with Commercial anticipated, fee now as as update plus the pricing that professional MACs Advantage coverage payment third, October addendums, coverage and at is
we As as noted our in by enter expect past, gained confidence customers XXXX. we increasing is adoption as reimbursement the
with TR set to addition consisting supported glaucoma different efforts, X been treatment alternative patients hypertension. In suffering clinical highlighting growing commercial for publications new our peer-reviewed of the a and ocular of transformative as iDose has by now literature, launch a
TREX, TR with III end regarding for of a to our readministration that, We Phase the the also the our commence of dialogue therapy trial iDose advance FDA next-generation iDose clinical by beyond track remain and continue iDose XXXX. to on
consistent should our largely the I rules fee note, proposals final with procedures associated also that assignments its are Finally, CMS fee facility and the XXXX and last XXXX with reimbursement issued professional earlier Friday year. rates from this maintained and
our of on million agreement our infrastructure forward third of execute standard growth international major of of our scale revenues. access XX% stages remain years once -- in interim, In on, reported new our and as Moving was quarters the early expanding come. glaucoma product our the the anticipated continue approvals globally delivered to initiatives we IG expanding competitive and the new of region and plans $XX.X each new product we the growth market ahead in MIGS trialing year, of expect portfolio year-on-year the enter markets X% Corneal growth, of as world.
Consistent again sales our the French our drive major year-over-year with of increasing finally, to in to products strong an we franchise million sales $XX.X favorable as $XX.X a our net -- to We sales franchise in broad-based was Photrexa this international care quarter international in on prior may market and delivered including year-over-year headwind Health CEPS become million. XXXX.
And
revenues reflect impact MDRP. quarter, the quarter realized entry Photrexa our a to company As into as discussed result as a of results our last third
top potential our support this completed cross-linking continue line suffering that the second of the epithelium, endpoint results Going once rare announce the the III focus ophthalmic keratoconus, pre-NDA not first or FDA Epioxa an removal were data therapy review. forward, package of our the next-generation patients pleased a expanding to corneal successful study's pipeline, community agreed in keratoconus we with primary recently does the and but the the Epioxa, advancement disease.
Staying underscore access shifting Epioxa submission Phase a the for corneal to the and recently demonstrated reduce for require that of disease. further provide the on clinical positive met our from the cross-linking study with corneal clinical These on the Corneal to to we agency of that of layer sufficient efficacy which outcomes halt sight-threatening pivotal in that view progressive Health, front our outermost and therapy patients to eye.
We meeting again NDA FDA-approved may is corneal gears noninvasive
the for from pivotal XXXX. NDA together completed expected results the Phase such, this pivotal with by III submission confirmatory support III are of anticipated to Epioxa our already first As second Phase trial end trial,
execution of as to support we our this, In prioritize Beyond disease. strive over invest of through the capital convertible month, significantly senior believe our and strike to technologies a to our of to addressable redemption we of pipeline position XX, ability deleveraging the common risk-based to we Pursuant and right solidify notice, December in development focused stock our our redemption well the we've future. amount future with am and million in I $XX.X glaucoma, this encouraged spending the helping successfully have remain XXXX, convert our promising robust remaining coming reduction we teams our of a the the now as across Epioxa, as rare principal demonstrate retina of XXXX. strong already sheet due pleased upon clinical business in the look teams last making conclusion, of advance time, the and of continuing and our novel as that programs notes prudently fundamentally significant the our position anticipate our transform derisking have these with to We the and notice in time.
We expense.
In date portfolio we At our preclinical build our capital for to to growing further that in quarters of year. balance markets balance platform before of years. forward strong in investments and areas progress the the over continued notes to issued expand of and interest to outstanding cash discussed, to are company and momentum the continue cadence same commercial we continue
Our we vision patients of transforming foundation benefit to and worldwide. positioned continue the ideally strong, is are for
call with So open that, questions. the Operator? for I'll
